Bracco molecular imaging subsidiary Blue Earth Diagnostics and Siemens Healthineers subsidiary PETNet Solutions have signed a new commercial supply contract for Blue Earth's Axumin (fluciclovine F-18) radiopharmaceutical and its investigational radiohybrid prostate-specific membrane antigen imaging agent, rhPSMA-7.3 (F-18).
Under the new multiyear deal, PETNet will expand production and continue distributing Axumin. It will also commercially manufacture and distribute rhPSMA-7.3 (F-18) pending its successful development and potential approval by the U.S. Food and Drug Administration (FDA), according to the companies. PETNet is already producing rhPSMA-7.3 (F-18) for Blue Earth's phase III clinical trials in patients with newly diagnosed or recurrent prostate cancer.
